CSIMarket
 
Savara Inc   (NASDAQ: SVRA)
Other Ticker:  
 
 
Price: $2.3400 $0.03 1.299%
Day's High: $2.37 Week Perf: -2.09 %
Day's Low: $ 2.31 30 Day Perf: 7.34 %
Volume (M): 741 52 Wk High: $ 4.74
Volume (M$): $ 1,735 52 Wk Avg: $3.24
Open: $2.32 52 Wk Low: $1.89



 Market Capitalization (Millions $) 506
 Shares Outstanding (Millions) 216
 Employees 25
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -102
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Savara Inc
Savara Inc is a clinical-stage biopharmaceutical company that is involved in the development of novel therapies for patients suffering from rare respiratory diseases. The company's primary focus is on conducting research and development programs targeted at designing and commercializing innovative treatment options for rare pulmonary conditions.

The company was founded in 2006 and is headquartered in Austin, Texas, USA. It operates as a public company, listed on the NASDAQ stock exchange under the symbol "SVRA." Savara Inc has a workforce of over 40 employees and is led by its executive team comprised of seasoned healthcare professionals with a track record of success in the industry.

Savara is currently engaged in several clinical development programs targeting cystic fibrosis (CF), a rare genetic disorder that affects the lungs and other organs. One of its key programs is molgramostim (GM-CSF) inhalation solution, which is aimed at treating patients with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease that affects only a few thousand people worldwide.

Other programs that Savara is working on include Aironite, an aerosol formulation targeted at treating several pulmonary indications characterized by inflammation and mucus hypersecretion, and AeroVanc, an inhaled vancomycin-based treatment designed for treating Methicillin-resistant Staphylococcus aureus (MRSA) lung infections in patients with CF.

Savara's platform technology enhances the delivery of inhaled medications, combining unique formulations with novel precision drug-delivery technologies to improve efficacy, safety, convenience, and patient outcomes.

To attract strategic partners and investors, Savara has entered into several collaborations and funding arrangements with leading healthcare organizations and industry partners. Most recently, the company partnered with the Cystic Fibrosis Foundation to advance its AeroVanc program's clinical development.

In summary, Savara Inc is a clinical-stage biopharmaceutical company involved in the development of innovative therapeutic solutions for rare respiratory diseases using its proprietary platform technology. Through its partnerships with leading healthcare organizations, the company is making significant strides towards providing effective treatment options to patients with rare pulmonary conditions, where there are currently limited treatment options.


   Company Address: 1717 Langhorne Newtown Road Langhorne 19047 PA
   Company Phone Number: 614-1848   Stock Exchange / Ticker: NASDAQ SVRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.18%    
BMY        0.04% 
JNJ        4.39% 
LLY   -3.46%    
MRK   -4.43%    
TEVA   -4.43%    
• View Complete Report
   



Announcement

Savara Inc. Under Scrutiny Pomerantz Law Firm Investigates Investor Claims Amid Market Volatility

Published Mon, Jun 2 2025 7:53 PM UTC

In a significant development for Savara Inc. (NASDAQ: SVRA), the Pomerantz Law Firm has announced that it is investigating potential claims on behalf of the company s investors. As the biotech sector continues to experience considerable fluctuations, investors are increasingly concerned about the implications for their portfolios, especially in companies such as Savara, whic...

Business Update

In a significant move aimed at bolstering its workforce, Savara Inc. (Nasdaq SVRA), a clinical-stage biopha...

Published Sat, Apr 12 2025 5:19 AM UTC

Savara Inc. Strengthens Talent Pool with Strategic Inducement Grants In a significant move aimed at bolstering its workforce, Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developing therapies for rare respiratory diseases, has announced the grant of inducement awards to seven new employees. This decision, made by the Compensation Commit...

Business Update

In an impressive maneuver that underscores its commitment to addressing rare respiratory diseases, Savara I...

Published Thu, Mar 27 2025 2:36 AM UTC

Savara Inc. Secures $200 Million Non-Dilutive Financing and Advances Pioneering Treatments for Rare Respiratory Diseases In an impressive maneuver that underscores its commitment to addressing rare respiratory diseases, Savara Inc. (Nasdaq: SVRA) has recently entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $200 million. This non-...

Business Update

Savara Inc. Strengthens Workforce Amid Promising Developments in Rare Respiratory Disease Treatments

Published Mon, Feb 17 2025 5:11 PM UTC

Savara Inc. (Nasdaq: SVRA), a leader in the clinical biopharmaceutical landscape focused on addressing rare respiratory diseases, is making significant strides both in its workforce recruitment and in advancing its clinical trials. Recent announcements from the company highlight not only its commitment to enhancing its talent pool through generous inducement awards but also ...

Business Update

Savara Inc. Submits FDA Application for MOLBREEVI to Treat Autoimmune Pulmonary Alveolar Proteinosis Follow...

Published Thu, Dec 19 2024 4:03 AM UTC

Savara Inc. Advances Toward Regulatory Approval for MOLBREEVI: Pioneering Treatment for Rare Lung Disease In an exciting development for patients with a rare and debilitating lung condition, Savara Inc. a clinical-stage biopharmaceutical company based in Langhorne, Pennsylvania, has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com